Literature DB >> 15694055

[Comparative clinical multicenter study to evaluate analgesic effectiveness of intramuscular etofenamate and diclofenac in patients with post-surgical pain].

Uriah Guevara-López1, Santos Uscanga-Sánchez, José Márquez, Juan Bárcenas-Olivares, Angeles Martínez-Arenas, José Antonio Palma-Aguirre.   

Abstract

OBJECTIVE: The analgesic efficacy of intramuscular etofenamate (1 g/day) and intramuscular diclofenac (75 mg/day) was assessed in post-surgical pain relief during a period of 3 days.
MATERIAL AND METHODS: One hundred ten hospitalized patients undergoing elective surgery were evaluated in an open-label, comparative, randomized, parallel-group, multicenter study. Fifty five patients received etofenamate and 55 patients diclofenac, 1 h before surgery. The doses were administered after 24 and 48 h. Baseline evaluations were carried out 30 min after anesthesia recovery and the clinical efficacy variables were assessed at 1, 6, 12, 24, 36, 48, 60 and 72 h. The efficacy variables were Pain Visual-Analogue Scale (VAS), Pain Analogous Verbal Scale (AVERS), and Well-Being Scale. Adverse events were documented.
RESULTS: Patients in both groups showed similar values in post-surgical pain relief (VAS, AVERS). According to VAS, etofenamate at 24 h had a better analgesic action than diclofenac even though it was not statistically significant. Both drugs demonstrated to be safe. Patients in both groups reported nausea, vomiting, flatulence, and pain at injection site.
CONCLUSIONS: We find that both etofenamate and diclofenac were safe, tolerable, and effective treatments for the relief of post-surgical pain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15694055

Source DB:  PubMed          Journal:  Cir Cir        ISSN: 0009-7411            Impact factor:   0.361


  1 in total

1.  Influence of preemptive analgesia on pulmonary function and complications for laparoscopic cholecystectomy.

Authors:  Meral Şen; Duygu Özol; Mikdat Bozer
Journal:  Dig Dis Sci       Date:  2009-12       Impact factor: 3.199

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.